Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...

Women’s health specialist Organon has entered into a definitive agreement to acquire Dermavant Sciences, a Roivant company.

Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

Roivant Sciences Ltd. has sold another company, this time offering up Dermavant Sciences Ltd. to Organon & Co. for $1.2 ...

Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an ...

18, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Ltd. announced today that ...